Sodium selenate - Velacor Therapeutics

Drug Profile

Sodium selenate - Velacor Therapeutics

Alternative Names: VEL-015

Latest Information Update: 20 Jul 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Velacor Therapeutics
  • Class Antidementias
  • Mechanism of Action Protein phosphatase 2A stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Alzheimer's disease

Most Recent Events

  • 20 Jul 2015 No recent reports on development identified - Phase-II for Alzheimer's disease (Early-stage disease) in Australia (PO)
  • 19 Feb 2013 Velacore Therapeutics initiates enrolment in a phase II trial for Alzheimer's disease (early-stage disease) in Australia (ACTRN12613000170729)
  • 16 Nov 2011 Phase-II clinical trials in Alzheimer's disease (early-stage disease) in Australia (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top